Created On: 2020-07-15
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28107
IPSCIO Record ID: 3285
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent therapy in patients whose disease recurred or did not respond to initial treatment
Follicular CD20-positive non-Hodgkin's lymphoma as an initial treatment with chemotherapy, and in patients whose initial treatment was successful, as a single-agent follow-up therapy
Low-grade or follicular CD20-positive non-Hodgkin's lymphoma as a single-agent follow-up therapy for patients who responded to initial treatment with CVP chemotherapy
IPSCIO Record ID: 46309
IPSCIO Record ID: 239007
Licensor grants a non-exclusive, irrevocable, perpetual, unrestricted worldwide right and license, without the right to sublicense, to make, have made, and use Licensed Know-How, for Licensees internal research and development purposes only.
Licensor grants a right of first negotiation and a right of first refusal to all Antibodies which bind to CD22 and to which a radiolabel is further attached, including, but not limited to, 90Y-Epratuzumab and 186Re-Epratuzumab; which are owned or controlled by Licensor on the Closing Date or during the term of this Agreement, collectively, the Radiolabeled Product(s)).
Licensor shall grant an exclusive first negotiating period of ninety (90) days to agree upon the terms and conditions of a separate licensing agreement for the development and commercialization of such Radiolabeled Product in the Field in the Territory.
(a) Epratuzumab and (b) any 2nd Generation Product for which Licensee provides notification to Licensor. In the event Licensee provides notification, the Antibody which is the subject of such notification shall be included within the definition of Product(s), subject to the terms and conditions of this Agreement (including for use solely in the Territory) relative to 2nd Generation Product(s) which may be included within the definition of Product(s).
The Radiolabeled Product(s)) are all Antibodies which bind to CD22 and to which a radiolabel is further attached, including, but not limited to, 90Y-Epratuzumab and 186Re-Epratuzumab; which are owned or controlled by Licensee on the Closing Date or during the term of this Agreement.
Licensed Trademark Rights shall mean any generic name (USAN/INN), trade name, logo or trademark (whether or not registered) in any country within the Territory owned (in whole or part) or controlled by Licensor as of the Closing Date – including LymphoCide.
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).